Postbiotics are a quickly-growing category of products targeting gut health and other applications, such as skin. Defined in 2021 as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the […]
The internationally recognized One Health Microbiome Center (OHMC) in the Huck Institutes of the Life Sciences at Penn State is the recipient of a new National Institutes of Health (NIH) grant to train doctoral students in biotechnological […]
As interest in biotics1 and their wide range of health applications continues to grow, BioGaia is proud to announce the launch of a subsidiary company, BioGaia New Sciences AB, dedicated to exploring opportunities in microbiome […]
A groundbreaking UK research network has been launched to uncover how the microbiota, gut, immune system and brain are inter-connected and how they can influence mental wellbeing. Work from the research network could potentially lead […]
Researchers have been working toward using the gut microbiome as a clinical target for screening for colorectal cancer. This would ideally allow simple stool tests to be used for early detection of the disease in […]
Danone announces the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics. In 2004, the team of Professor Willem M. de Vos at Wageningen University discovered, […]
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, announced today it has entered a strategic partnership with YUN NV, an innovative leader in microbiome skincare solutions. This collaboration is set to transform the […]
With Expert’Biome™, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strains research and development, bioprocesses scaling, drug manufacturing, and […]
An article published in Cell summarizes results of research and possible future clinical applications of the microbiome and provides instructions for doctors. More communication is needed between basic and clinical research to accelerate the arrival […]
32 Biosciences announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key […]
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the […]